.

Deeper Knowledge, Faster

  • Find suppliers and generic API sources
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

AstraZeneca
Cerilliant
Cipla
Fish and Richardson
UBS
Teva
Farmers Insurance
Covington
Federal Trade Commission
Julphar

Generated: June 28, 2017

DrugPatentWatch Database Preview

Details for Patent: 8,338,642

« Back to Dashboard

Which drugs does patent 8,338,642 protect, and when does it expire?


Patent 8,338,642 protects AURYXIA and is included in one NDA.

This patent has sixty-seven patent family members in nineteen countries.

Summary for Patent: 8,338,642

Title:Ferric organic compounds, uses thereof and methods of making same
Abstract: The present invention discloses a novel form of ferric organic compounds, including a form of ferric citrate, which are soluble over a wider range of pH, and which have a large active surface area. The ferric organic compounds of the present invention can be delivered effectively by oral route with better delivery to treat patients suffering from hyperphosphatemia, metabolic acidosis and other disorders responsive to ferric organic compound therapy.
Inventor(s): Kwok; David W. K. (Vancouver, CA), Stoynov; Nikolay Mintchev (Vancouver, CA)
Assignee: Panion & BF Biotech, Inc. (TW)
Application Number:12/711,679
Patent Claim Types:
see list of patent claims
Formulation; Compound; Dosage form; Use; Composition;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Keryx Biopharms
AURYXIA
ferric citrate
TABLET;ORAL205874-001Sep 5, 2014RXYesYes8,338,642► SubscribeYY CONTROL OF SERUM PHOSPHOROUS LEVELS
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Patent: 8,338,642

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,609,896Ferric organic compounds, uses thereof and methods of making same► Subscribe
8,754,258Ferric organic compounds, uses thereof and methods of making same► Subscribe
7,767,851Ferric organic compounds, uses thereof and methods of making same► Subscribe
8,299,298Pharmaceutical-grade ferric organic compounds, uses thereof and method of making same► Subscribe
9,328,133Ferric organic compounds, uses thereof and methods of making same► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 8,338,642

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
European Patent Office1978808► Subscribe
China105616397► Subscribe
Cyprus1115602► Subscribe
Denmark1601680► Subscribe
Denmark1931689► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Cerilliant
Accenture
QuintilesIMS
Teva
Express Scripts
Deloitte
Daiichi Sankyo
Dow
Argus Health
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot